Related Experiment Video

Updated: Apr 25, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer

A L Kasinski1, K Kelnar2, C Stahlhut3

  • 11] Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA [2] Department of Biological Sciences, Purdue University, West Lafayette, IN, USA.

Oncogene
|September 2, 2014
PubMed

Insights

Combining two microRNAs (miRNAs) using nanodelivery effectively suppressed non-small cell lung cancer growth in mice. This novel approach offers a safe and potent strategy for targeted cancer therapy, overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Nanotechnology

Background:

  • Targeted cancer therapies face limitations due to drug resistance.
  • Combinatorial treatments can overcome resistance by targeting multiple pathways.
  • MicroRNA mimics show promise for simultaneously repressing oncogenic pathways.

Purpose of the Study:

  • To evaluate the efficacy of a combination of two tumor-suppressive microRNAs (miRNAs) in a Kras;p53 non-small cell lung cancer mouse model.
  • To assess the safety and effectiveness of systemic nanodelivery for combinatorial miRNA therapy.

Main Methods:

  • Treatment of an aggressive Kras;p53 non-small cell lung cancer mouse model.
  • Systemic administration of miR-34 and let-7 mimics via nanodelivery.
  • Monitoring of tumor growth and survival advantage.

Main Results:

  • The combination of miR-34 and let-7 significantly suppressed tumor growth.
  • Systemic nanodelivery of these miRNAs resulted in a survival advantage for the treated mice.
  • The combinatorial miRNA therapy engaged multiple tumor cell-addictive pathways.

Conclusions:

  • Combinatorial miRNA therapy, delivered via nanocarriers, is a safe and effective strategy for targeting non-small cell lung cancer.
  • This approach demonstrates potential for overcoming therapeutic resistance in lung cancer.
  • Targeting multiple oncogenic pathways simultaneously with miRNAs offers a promising avenue for cancer treatment.

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

551
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K